Risultati della ricerca - Christine A. Pratilas
- Mostra 1 - 20 risultati su 39
- Vai alla pagina seguente
-
1
-
2
Targeting Oncogenic BRAF in Human Cancer di Christine A. Pratilas, Feng Xing, David B. Solit
Pubblicazione 2010Artigo -
3
-
4
BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors di Karisa C. Schreck, Stuart A. Grossman, Christine A. Pratilas
Pubblicazione 2019Revisão -
5
-
6
Identification of Unique MEK-Dependent Genes in GNAQ Mutant Uveal Melanoma Involved in Cell Growth, Tumor Cell Invasion, and MEK Resistance di Grazia Ambrosini, Christine A. Pratilas, Li-Xuan Qin, Madhavi Tadi, Oliver Surriga, Richard D. Carvajal, Gary K. Schwartz
Pubblicazione 2012Artigo -
7
-
8
-
9
-
10
-
11
BRAFV600E Mutation Is Associated with Preferential Sensitivity to Mitogen-Activated Protein Kinase Kinase Inhibition in Thyroid Cancer Cell Lines di Rébecca Leboeuf, Jacqueline E. Baumgartner, Miriam Benezra, Roberta Malaguarnera, David B. Solit, Christine A. Pratilas, Neal Rosen, Jeffrey A. Knauf, James A. Fagin
Pubblicazione 2008Artigo -
12
3′-Deoxy-3′-[18F]Fluorothymidine Positron Emission Tomography Is a Sensitive Method for Imaging the Response of BRAF-Dependent Tumors to MEK Inhibition di David B. Solit, Elmer Santos, Christine A. Pratilas, Jose Lobo, Maxim A. Moroz, Shangde Cai, Ronald Blasberg, Judith S. Sebolt‐Leopold, Steven M. Larson, Neal Rosen
Pubblicazione 2007Artigo -
13
Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in <i>EGFR</i>-Mutant Lung Cancer di Erin M. Tricker, Chunxiao Xu, Sharmeen Uddin, Marzia Capelletti, Dalia Ercan, Atsuko Ogino, Christine A. Pratilas, Neal Rosen, Nathanael S. Gray, Kwok‐Kin Wong, Pasi A. Jänne
Pubblicazione 2015Artigo -
14
Adaptation to TKI Treatment Reactivates ERK Signaling in Tyrosine Kinase–Driven Leukemias and Other Malignancies di J. Kyle Bruner, S. Hayley, Li Li, Alice Can Ran Qin, Michelle A. Rudek, Richard J. Jones, Mark J. Levis, Keith W. Pratz, Christine A. Pratilas, Donald Small
Pubblicazione 2017Artigo -
15
Novel PAX3::MAML3 fusion identified in alveolar rhabdomyosarcoma, using DNA methylation profiling to expand the genetic spectrum of “fusion-positive” cases di Josephine K. Dermawan, Faizan Malik, John Gross, Ezra Baraban, Christine A. Pratilas, Wadad Mneimneh, Matteo Trucco, Wenyue Sun, Frederic G. Barr, Felipe D’Almeida Costa, Karen Fritchie
Pubblicazione 2024Artigo -
16
Perturbation biology nominates upstream–downstream drug combinations in RAF inhibitor resistant melanoma cells di Anil Korkut, Weiqing Wang, Emek Demir, Bülent Arman Aksoy, Xiaohong Jing, Evan Molinelli, Özgün Babur, Debra L. Bemis, S. Onur Sumer, David B. Solit, Christine A. Pratilas, Chris Sander
Pubblicazione 2015Artigo -
17
Size-based detection of sarcoma circulating tumor cells and cell clusters di Masanori Hayashi, Peixuan Zhu, Gregory McCarty, Christian F. Meyer, Christine A. Pratilas, Adam S. Levin, Carol D. Morris, Catherine M. Albert, Kyle W. Jackson, Cha-Mei Tang, David M. Loeb
Pubblicazione 2017Artigo -
18
Eosinophilic Solid and Cystic (ESC) Renal Cell Carcinomas Harbor TSC Mutations di Doreen N. Palsgrove, Yunjie Li, Christine A. Pratilas, Ming‐Tseh Lin, Aparna Pallavajjalla, Christopher D. Gocke, Angelo M. De Marzo, Andrés Matoso, George J. Netto, Jonathan I. Epstein, Pedram Argani
Pubblicazione 2018Artigo -
19
-
20
The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner di Eric W. Joseph, Christine A. Pratilas, Poulikos I. Poulikakos, Madhavi Tadi, Weiqing Wang, Barry S. Taylor, Ensar Halilovic, Yogindra Persaud, Feng Xing, Agnès Viale, James Tsai, Paul B. Chapman, Gideon Bollag, David B. Solit, Neal Rosen
Pubblicazione 2010Artigo
Strumenti per la ricerca:
Soggetti correlati
Biology
Cancer research
Medicine
Gene
Genetics
Cancer
MAPK/ERK pathway
Cell biology
Kinase
Internal medicine
Signal transduction
Mutation
MEK inhibitor
Oncology
Biochemistry
Melanoma
Pathology
KRAS
Mutant
Bioinformatics
Immunology
Lung cancer
Pharmacology
V600E
Chemistry
Colorectal cancer
Computational biology
Computer science
Metastatic melanoma
PI3K/AKT/mTOR pathway